Aim immunotech publishes phase 1 clinical study data supporting the safety of ampligen as an intranasal therapy

Ocala, fla., oct. 06, 2021 (globe newswire) -- aim immunotech inc. (nyse american: aim) today released detailed safety data from a phase 1 clinical study which supports the company's belief that its drug ampligen has significant potential as an intranasal therapeutic for covid-19.

AIM Ratings Summary

AIM Quant Ranking